Leprosy Mailing List – July 27, 2018
Ref.: (LML) Manifest against the implementation of U-MDT
From: Joydeepa Darlong and SR. Narahari, India
Dear Pieter,
Clofazemine is not acceptable in children. We force it on MB children and they take it with a great deal of unhappiness. Off record, most mothers confess that their children do not swallow clofazemine. Among those that do discoloration leads to maximum school dropouts and defaults. And we all now that maximum children are PB cases. Its unfair to thrust clofazemine on them.
Regards,
Joydeepa Darlong
Head Knowledge management
The leprosy Mission Trust India
Dear Dr Schreuder,
Dermatologist Ajit (LML, July 26, 2018) has raised very relevant questions faced in daily practice in India. All of us running small clinics employing a few people who manage a portion of disease burden in the country.
Without publications I wish to say presentation has changed and dapsone side effects are increasing. I am seeing a patient presenting with haematuria for two weeks before skin rash. Later high neutrophils persist for a few weeks. Leprosy is not that common in Kerala but yes, it is coming back with more complex presentations and is beginning to challenge the present treatment regimens!
SR Narahari
LML - S Deepak, B Naafs, S Noto and P Schreuder
LML blog link: http://leprosymailinglist.blogspot.it/
Contact: Dr Pieter Schreuder << editorlml@gmail.com
No comments:
Post a Comment